5 Ways To Adapt Your Neurodegenerative Disease Trial To The World Of COVID-19

Why Is The Success Rate So Dismal? What Can You Do From The Start To Avoid A Failed Early-Phase Study?

When COVID-19 exploded around the world, in-progress neurodegenerative disease trials – as well as studies preparing to launch – were faced with a sudden and unexpected challenge: how to adapt their approach with the least disruption possible.

Operational complexity skyrocketed overnight, creating challenges for safety assessments, visit conduct, drug delivery, documentation, staff training, budget control, patient risk management, and more. As many sponsors learned, not all drug programs adapted successfully.

If your study is struggling to reinvent its tactics in the face of COVID-19, consider these tips for changes in logistics and study delivery methods to preserve your program’s data integrity and facilitate completion during these trying times.